ABSI · XBRL financial data

Absci financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ABSI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	4,782	5,747	5,718	4,534	—
Research and development	44,586	58,908	48,067	63,859	81,418
Selling, general and administrative	28,780	40,552	37,832	36,174	35,058
Total operating expenses	80,020	112,497	121,233	113,422	123,117
Operating income (loss)	(75,238)	(106,750)	(115,515)	(108,888)	(120,317)
Interest expense	3,432	972	1,010	565	209
Other income (expense)	(31,189)	2,357	6,059	6,417	5,412
Income tax expense (benefit)	(8,899)	(461)	100	70	69
Net income (loss)	(100,960)	(104,904)	(110,566)	(103,106)	(115,183)
Earnings per share, basic USD per share	(2.08)	(1.15)	(1.20)	(0.94)	(0.84)
Earnings per share, diluted USD per share	(2.08)	(1.15)	(1.20)	(0.94)	(0.84)
Weighted average shares, basic thousands of shares	49,685	90,846	92,028	110,240	136,777
Weighted average shares, diluted thousands of shares	49,685	90,846	92,028	110,240	136,777

Fiscal years (ABSI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	252,569	59,955	72,362	41,213	20,025
Marketable securities	0	—	—	71,212	124,267
Marketable securities, non-current	—	—	—	—	11,800
Accounts receivable	—	—	2,189	0	—
Prepaid and other current assets	8,572	5,859	4,537	5,459	5,281
Total current assets	273,079	186,863	120,578	133,831	149,573
Right-of-use asset	6,538	5,319	4,490	3,968	2,914
Goodwill	21,335	21,335	0	—	—
Total assets	426,195	321,008	217,298	213,608	216,297
Accounts payable	8,385	2,412	1,503	3,529	2,756
Accrued liabilities	17,434	20,481	19,303	6,842	—
Total current liabilities	33,859	30,270	29,558	28,656	22,765
Lease liability, non-current	8,969	7,317	5,643	4,429	2,624
Total liabilities	60,088	46,594	41,122	34,475	26,848
Accumulated deficit	(191,025)	(295,929)	(406,495)	(509,601)	(624,784)
Total stockholders' equity	366,107	274,414	176,176	179,133	189,449
Total liabilities and equity	426,195	321,008	217,298	213,608	216,297
Common shares outstanding (cover page) thousands of shares	92,773	92,322	112,785	127,334	153,021

Fiscal years (ABSI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(100,960)	(104,904)	(110,566)	(103,106)	(115,183)
Stock-based compensation	10,608	12,540	11,416	19,452	18,321
Depreciation and amortization	6,654	13,037	13,999	13,389	11,742
Net cash from operating activities	(60,598)	(81,339)	(64,636)	(72,402)	(92,925)
Purchases of property and equipment	38,047	16,175	860	404	1,107
Net cash from investing activities	(67,377)	(126,982)	81,944	(41,577)	(50,160)
Proceeds from issuing common stock	210,396	656	862	82,398	105,835
Repayments of long-term debt	1,600	4,651	3,012	3,388	3,117
Net cash from financing activities	336,193	5,237	(4,483)	82,526	105,949
Net change in cash	208,218	(203,084)	12,825	(31,453)	(37,136)

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Absci	107,865	not reported	(27,564)*	171.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
Maxcyte	15,042	7,271	(4,661)*	103.2M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
NRC Health	3,626	38,399	8,020*	21.2M	—	Q3 FY26 10-QSep 30, 2026
OmniAb	22,883	3,993	10,575*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Neogenomics	139,281	209,254	(8,885)*	129.4M	18.9 quarters	Q3 FY26 10-QSep 30, 2026
20/20 Biolabs	4,546	731	(605)*	12.8M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Inotiv	15,180	117,652	(1,070)*	34.9M	14.2 quarters	Q2 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.